Cancer Research UK reports positive Phase III OAK trial of atezolizumab in treating lung cancer

Cancer Research UK has reported that the Phase III OAK clinical trial of atezolizumab (Tecentriq) conducted by German-based University Goettingen to treat patients with lung cancer has achieved positive results.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news